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Background: Most of what is known regarding the epidemiology of mortality from heart failure (HF) comes from
studies within Western populations with few data available from the Asia-Pacific region where the burden of heart
failure is increasing.
Methods: Individual level data from 543694 (85% Asian; 36% female) participants from 32 cohorts in the Asia Pacific
Cohort Studies Collaboration were included in the analysis. Adjusted hazard ratios (HR) and 95% confidence intervals
(CI) for mortality from HF were estimated separately for Asians and non-Asians for a quintet of cardiovascular risk
factors: systolic blood pressure, diabetes, body mass index, cigarette smoking and total cholesterol. All analyses were
stratified by sex and study.
Results: During 3,793,229 person years of follow-up there were 614 HF deaths (80% Asian). The positive associations
between elevated blood pressure, obesity, and cigarette smoking were consistent for Asians and non-Asians. There was
evidence to indicate that diabetes was a weaker risk factor for death from HF for Asians compared with non-Asians: HR
1.26 (95% CI: 0.74-2.13) versus 3.04 (95% CI 1.76-5.25) respectively; p for interaction = 0.022. Additional adjustment for
covariates did not materially change the overall associations. There was no good evidence to indicate that total
cholesterol was a risk factor for HF mortality in either population.
Conclusions: Most traditional cardiovascular risk factors including elevated blood pressure, obesity and cigarette
smoking appear to operate similarly to increase the risk of death from HF in Asians and non-Asians populations alike.
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Heart failure (HF) is a complex syndrome with a multi-
factorial aetiology and is a major cause of death and dis-
ability in higher-income countries where it is estimated
that 2% of adults are affected [1]. The incidence of HF is
strongly age-related so that the prevalence of the con-
dition rises to 6-10% in those over 65 years of age [1]. In
the United States (US) alone, an estimated 550,000 new
cases occur annually [2] and in 2008, 1 in 9 death certifi-
cates mentioned heart failure [3]. Globally, it has been
estimated that 23 million individuals worldwide have HF
[4] although this may be an underestimate given the lack
of reliable population-based studies of the prevalence
and incidence of HF for Asia and elsewhere [5,6]. What
data there are from Asia suggest that hospitalization for
HF is increasing in the region [7,8].
Our knowledge regarding the causes of HF has chiefly
been derived from studies from the US [9] and Europe
[10] with relatively few data from less developed parts of
the world including Asia [11]. As with other forms of
cardiovascular disease, the major lifestyle risk factors for
HF are reported to include elevated blood pressure,
obesity, smoking, and diabetes [12]. Whether these risk
factors exert the same effect on Asian populations that
tend to have markedly different risk factor profiles com-
pared with non-Asians [13] remains to be determined.
In this paper we report on the associations between
traditional cardiovascular risk factors and mortality from
HF in the Asia-Pacific region and contextualize these
findings with respect to the current literature using data
from the Asia Pacific Cohort Studies Collaboration
(APCSC) [14,15].
Methods
Ethics approval
All of the individual studies that participated in APCSC
obtained ethics approval from their own ethics approval
boards. All participants were aged 18 or over and pro-
vided informed consent in accordance with the princi-
ples of the Declaration of Helsinki.
Details of the APCSC have been described elsewhere
[14,15]. In brief, a study was eligible for inclusion if the
population was drawn from the Asia Pacific region; it had
a prospective cohort study design without selection being
consequent to pre-existing disease; it had accumulated at
least 5000 person-years of follow-up; date of birth (or
age), sex and blood pressure were recorded at baseline;
and date or age at death was recorded during follow-up.
Cohorts were excluded if they were based on a positive
disease history or diagnosis. Cohorts were classified as
Asian if the participants were recruited from mainland
China, Hong Kong, South Korea, Japan or Taiwan, and
Australian if the cohorts were recruited within Australia.
The majority of cohorts were population-based but severalof the cohorts were sourced from occupational settings
(e.g. KMIC, Guangzhou Occupational, Beijing Steel-
workers, and Civil Service Workers).
In most studies, blood pressure was measured at rest in
the seated position using a standard mercury sphyg-
momanometer [16]. TC was obtained using previously
described methods [17]. Body mass index (BMI) was cal-
culated as weight (kg) divided by squared height (m2) [18].
The diabetes status of individual participants was deter-
mined on the basis of a self-reported history of diabetes at
baseline or by applying the World Health Organization
(WHO) criteria to baseline blood glucose levels [19].
Cigarette smoking was classified based on self-report at
baseline as ‘ever’ versus ‘never’ smoking [20].
End-point
Most studies used database linkage to identify deaths,
while others also included scheduled follow-up visits or
examined hospital records Information on fatal events
was classified according to the Ninth Revision of the
International Classification of Diseases (ICD-9). The end
point considered in this analysis was fatal HF (ICD-9
428). Data quality of the individual cohorts was centrally
checked and, if needed, data were recoded for compar-
ability across studies. Where necessary, further details
were sought from the principal investigators of each in-
dividual study.
Statistical analyses
All analyses used individual participant data, restricted to
participants aged ≥20 years at the time of the baseline
survey. Cox proportional hazards regression was used to
estimate hazard ratios (HRs) and 95% confidence intervals
(95% CI) for HF for each risk factor, after adjustment for
age. All analyses were stratified by sex and study. For linear
associations HRs for a unit increase were derived. BMI
and HF exhibited a non-linear relationship so the HRs
across quarters were reported. In addition, the HR’s across
five sequential categories of BMI were reported: <18.5,
18.5–21.9, 22–24.9, 25–29.9 and ≥30 kg/m2 [21]. The
95% CI for categories of BMI were obtained by the method
of floating absolute risks [22]. The associations for con-
tinuous variables were adjusted for regression dilution bias
using repeated measurement data [23]. The analyses were
repeated within subgroups according to sex, age (≤75 v >
75 years), and region (Asia v Australia) and a p-value less
than 0.05 was considered evidence of an interaction. In a
sensitivity analysis, the impact of adjustment for SBP,
smoking, BMI and diabetes was explored using a restricted
sample that had information on these variables. In a
further sensitivity analysis, the data were left-censored to
exclude events that occurred during the first two years of
follow-up. We also examined whether there was an inter-
action with history of cardiovascular disease at study
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model. Data provided to the Secretariat were checked for
completeness and consistency and recoded, when neces-
sary, to maximize comparability across cohorts. Summary
reports were referred back to principal investigators of
each collaborating study for review and confirmation.
Analyses were performed using SAS, version 9.2 and Stata
version 11.
Results
A total of 543694 (85% Asian; 36% female) participants
from 32 cohorts were included in this analysis (Table 1).
Due to missing values for some variables, the number of
subjects available for analysis varied according each to
risk factor.
Systolic blood pressure
Overall, 3,793,229 person years of follow-up data con-
tributed to the analysis of SBP with HF during which
time 614 deaths (80% Asian) from HF were recorded. In
the Asian cohorts, 56% of HF deaths were from Japan,
42% from China and the remainder from Hong Kong,
Taiwan, Japan and Korea. There was a significant and
linear positive association between SBP and the risk of
mortality from HF (p = 0.0003). Every 10 mmHg incre-
ment in SBP increased the risk by 13% (95% CI: 6-21%)
with no evidence that the effect varied by sex (p = 0.28)
or region (p = 0.93, Figure 1). There was a highly signifi-
cant interaction with age (p < 0.0001), such that the as-
sociation was only observed for younger compared with
older individuals: HR 1.27 (1.15-1.39) and HR 1.00
(0.92-1.09) in individuals ≤75 years and >75 years, re-
spectively. Adjusting for smoking, BMI and diabetes did
not materially change the associations (Additional file 1:
WebFigure 1). There was some evidence that the asso-
ciation differed by whether or not the individual had a
history of cardiovascular disease (CVD) at study baseline
(Additional file 1: WebTable 1); In those individuals with
no CVD history, there was a positive association whereas
there was no apparent association between SBP and
heart failure mortality in those with a history of CVD
(p interaction with history of CVD = 0.024). This may have been
a chance finding due to the small number (<100) of
events that occurred in those with a history of CVD.
Body mass index
The age-adjusted analysis between BMI and HF mor-
tality was based on a total of 2,430,378 person-years and
494 events. There was a U-shaped relationship across
quarters of BMI (Figure 2), with the second and third
quarters having the lowest risk of mortality compared
with the first quarter. There was no indication that the
association differed by region (p = 0.86), sex (p = 0.65),
or age (p = 0.95). When the relationship was examinedusing the pre-specified categories for weight with normal
weight (18.5–21.9 kg/m2) as the reference group the
U-shaped relation was more evident (Table 2). Com-
pared with the reference group, both underweight and
obese individuals had more than a 60% increased risk of
dying from HF compared with normal weight individuals:
HR 1.68 (95% CI: 1.34-2.11) and 1.69 (1.17-2.43) for
underweight and obese individuals, respectively which
remained unchanged after adjustment for cigarette smo-
king or after two years left censoring (Table 2). The
relationship was consistent in those with and without a
history of CVD at study baseline (p interaction with history of
CVD = 0.92; Additional file 1: WebTable 1).
Lifetime cigarette smoking
A total of 3,443,811 person years and 579 events con-
tributed to this analysis. Compared with never smokers
ever smoking was significantly associated with 30%
increased risk of mortality (95% CI: 6-60%; Figure 3).
There was no evidence that the association differed by re-
gion (p = 0.073), sex (p = 0.60) or age (p = 0.064). The re-
sults remained largely unchanged after adjusting for SBP
and BMI (Additional file 1: WebFigure 2). The relation-
ship was consistent in those with and without a history of
CVD at study baseline (p interaction with history of CVD = 0.10;
Additional file 1: WebTable 1).
Diabetes
Based on 1,996,642 person years of data and 496 events,
individuals with diabetes had 80% (95% CI: 1.24-2.63)
greater risk of death from HF compared with those with-
out the condition, with no evidence to suggest that the
relationship differed significantly by sex (p = 0.59) or by
age (p = 0.21) (Figure 4). There was suggestive evidence
of a stronger effect in cohorts from Australia compared
with Asia: HR 3.04 (1.76-5.25) versus 1.26 (0.74-2.13)
(p = 0.022). There was no material change in these associ-
ations once the effect of other covariates was considered
(Additional file 1: WebFigure 3). The relationship was
consistent in those with and without a history of CVD
at study baseline (p interaction with history of CVD = 0.15;
Additional file 1: WebTable 1).
Total cholesterol
Information on the association between TC and HF was
based on 2,145,819 person years and 365 events. Test for
linearity indicated that there was a weak inverse asso-
ciation between TC and HF (p = 0.01). A 1 mmol/L in-
crement in TC was associated with a non-significant
reduction in HF mortality with no significant evidence
of a regional interaction: HR 0.90 (95% CI: 0.77-1.07);
p = 0.059; Figure 5. The HR remained largely unchanged
after additional adjustment for cigarette smoking, SBP and
BMI: HR 0.93 (0.77-1.11) per 1 mmol/L increase in TC
Table 1 Baseline characteristics of participating studies in Australia and Asia in the Asia Pacific Cohort Studies
Collaboration
Study name (Country) N Baseline
years
Female (%) Age
(yrs)
HF
deaths
FU
(yrs)
SBP
(mmHg)
BMI
(kg/m2)
TC
(mmol/L)
Diab (%) Smoke (%)
ALSA (Aus) 1613 1992-93 48 78 20 5 148 26.0 5.8 8.3 7.7
ANHF (Aus) 9277 1989-90 51 43 3 8 126 25.4 5.5 1.9 24.1
Busselton (Aus) 7866 1966-81 52 45 50 27 138 24.6 5.9 3.5 33.8
Canberra (Aus) 833 1990-91 46 77 16 9 145 - - 6.8 11.3
Melbourne (Aus) 41286 1990-94 59 55 18 9 138 26.9 5.5 5.4 11.3
Perth (Aus) 10230 1978-94 48 45 5 14 130 25.2 5.8 2.1 25.5
WAAAA Screenees (Aus) 12203 1996-99 0 72 10 3 157 26.9 - 11.6 10.9
Total Australia 83308 47 55 122 8 139 26.3 5.6 5.4 16.4
Aito Town (Japan) 1717 1980-83 57 51 9 15 136 22.6 4.6 2.7 28.6
Akabane (Japan) 1836 1985-86 56 54 16 11 125 22.5 5.0 2.5 28.0
Anzhen (China) 8378 1991 55 54 3 4 129 23.9 - 0.0 28.5
Beijing Steelworkers (China) 8957 1970 12 36 15 28 123 - - - -
Civil Service Workers (Japan) 9319 1990-92 33 47 1 7 126 22.5 5.2 1.8 37.9
CVDFACTS (Taiwan) 5730 1988-96 55 47 4 6 118 23.5 5.0 2.7 22.2
East Beijing (China) 1128 1977-94 51 44 3 17 125 23.6 - 5.6 28.6
Fangshan (China) 2625 1991-92 67 47 1 4 136 24.4 4.6 7.1 39.3
Guangzhou Occupational (China) 167377 1985-97 22 42 11 7 115 22.6 5.3 10.5 47.6
Hisayama (Japan) 1616 1961 56 56 24 25 135 21.6 4.1 0.0 42.7
Hong Kong 3006 1985-91 58 79 4 3 150 21.9 5.3 8.6 18.6
Huashan (China) 1868 1990-92 52 53 2 3 126 23.3 4.6 13.7 24.9
Kinmen (Taiwan) 2793 1993-96 48 63 90 3 137 23.4 - 8.6 8.3
KMIC (Korea) 183600 1992 37 44 7 4 122 23.0 5.0 7.7 38.5
Konan (Japan) 1226 1987-95 55 52 9 6 130 21.9 4.9 12.6 30.1
Miyama (Japan) 1078 1988-90 56 61 11 7 132 22.1 5.1 0.0 29.5
Ohasama (Japan) 2240 1992-93 64 60 4 4 128 23.3 5.0 10.9 20.0
Saitama (Japan) 3624 1986-90 62 55 28 11 135 22.4 5.0 1.7 28.4
Seven Cities Cohorts (China) 10811 1987 55 54 139 3 130 22.6 5.0 1.2 35.1
Shibata (Japan) 2350 1977 58 57 34 20 131 22.4 4.6 1.1 33.1
Shigaraki Town (Japan) 3758 1991-97 60 57 7 4 132 22.5 5.0 7.2 28.8
Shirakawa (Japan) 4643 1974-79 54 48 27 18 127 21.5 4.6 0.9 34.9
Six Cohorts (China) 19387 1982-86 47 45 6 9 119 21.2 4.2 0.0 46.0
Tanno/Soubetsu (Japan) 1984 1977 53 51 16 16 133 23.6 4.9 7.2 38.6
Tianjin (China) 9335 1984 51 55 21 6 136 23.5 - 0.0 50.9
Total Asia 460386 34 45 492 6 121 22.8 4.9 6.9 41.4
Total 543694 36 46 614 7 124 23.6 5.1 6.5 37.3
FU =mean follow-up in years; SBP = systolic blood pressure; TC = total cholesterol; diab = diabetes; HF = death from heart failure; NHS = National Health Survey;
ALSA = Australian Longitudinal Study of Aging; ANHF = Australian National Heart Foundation. WAAAA =West Australian Abdominal Aortic Aneurysm; CISCH =
Capital Iron and Steel Hospital; KMIC = Korean Medical Insurance Corporation. - = no data available.
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terial effect after excluding the first two years of follow
up (HR 0.98 [95% CI 0.81-1.17]). The relationship was
consistent in those with and without a history of CVD
at study baseline (p interaction with history of CVD = 0.45;
Additional file 1: WebTable 1).Discussion
This study comprises the largest amount of prospective
data to date on the relationship between major cardiovas-
cular risk factors with HF mortality in populations from
the Asia-Pacific region. The key findings from this indi-
vidual participant data meta-analysis indicate positive and
Figure 1 Hazard ratios for fatal heart failure associated with a 10 mmHg increment in systolic blood pressure, adjusted for age and
regression dilution bias and stratified by sex and study in the Asia Pacific Cohort Studies Collaboration, both by subgroup (male
versus female; Asia versus Australia; ≤ 75 yrs vs > 75 yrs) and overall. Bars show 95% confidence intervals. The vertical dimension of the
diamond indicates the overall estimate and the horizontal dimension indicates the 95% confidence interval.
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sure, obesity, diabetes and cigarette smoking with death
from HF in Asians and non-Asians, but no evidence of
an association with TC. With the possible exception for
blood pressure, the relationships were consistent in
those with and without a history of CVD at study base-
line. Overall, these current findings are broadly consis-
tent with those reported from Western population-based
studies, including Framingham [24,25] and NHANES
[12]. Both of these US studies reported hypertension to be
a major, if not the leading, modifiable cause of incident
HF in addition to diabetes, smoking and obesity [24,25].Figure 2 Hazard ratios for fatal heart failure by fourths of body mass
and study. Bars show 95% confidence intervals. Baseline fourths were ≤21Comparative population-based data from Asia are sparse,
but those derived from hospital-based studies have also in-
dicated the frequently high co-occurrence of hypertension
and diabetes among individuals hospitalized for HF [26].
That diabetes may also be an independent risk factor
for incident HF was first shown by the Framingham
study where a clinical history of diabetes was associated
with a two-fold increased risk in men and a five-fold in-
creased risk for women [25]. Since then, numerous stu-
dies have reported higher incidence rates of HF among
those with diabetes compared with those without the
condition, as well as a relatively higher relative risk ofindex adjusted for age and regression dilution; stratified by sex
.1, 21.2-23.2, 23.3-25.4, ≥25.5 kg/m2.
Table 2 The categorical association between body mass index (BMI) and mortality from heart failure in the Asia Pacific
Cohort Studies Collaboration
BMI category (kg/m2) Age, sex and study adjusted Age, sex, study, smoking adjusted 2-year left censored
HF deaths HR (95% CI) HF deaths HR (95% CI) HF deaths HR (95% CI)
< 18.5 (underweight) 100 1.68 (1.34-2.11) 100 1.72 (1.37-2.16) 79 1.78 (1.37-2.30)
18.5 – 21.9 (normal, ref) 157 1.00 (0.84-1.18) 151 1.00 (0.84-1.19) 125 1.00 (0.83-1.21)
22 – 24.9 103 0.81 (0.67-0.98) 101 0.83 (0.68-1.01) 87 0.86 (0.69-1.05)
25 – 29.9 (overweight) 91 0.98 (0.80-1.22) 90 1.02 (0.83-1.27) 76 1.04 (0.82-1.31)
> 30 (obese) 33 1.69 (1.17-2.43) 33 1.76 (1.22-2.54) 27 1.75 (1.16-2.63)
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Data from the current study, confirmed an independent
association between diabetes and mortality from HF for
non-Asians and (to a lesser extent) Asians. That diabetes
may have a slightly weaker association with mortality
from HF in Asians than in non-Asians is an intriguing
finding that warrants further investigation.
In the current study, a U-shaped association between
BMI and mortality from HF was observed such that in-
dividuals who were either underweight or obese were at
similarly greater risk of dying from HF compared with
those of normal weight. This remained unaffected by ad-
justment for smoking, which may have operated as a
confounder of the association given that smokers tend
to be relatively leaner than their non-smoking counter-
parts. Efforts to reduce the impact of reverse causality
by excluding the first two years of follow-up also had lit-
tle impact on the relationship. Our observation that
underweight is a risk factor for mortality from HF is tan-
gentially supported by previous hospital-based studies
that have shown patients with chronic HF who are
underweight have a lower survival than those of normalFigure 3 Hazard ratios for fatal heart failure associated with cigarette
sex and study in the Asia Pacific Cohort Studies Collaboration. Conveweight or who are overweight or obese [29]. The in-
creased risk of HF death for underweight individuals
may be due to cardiac cachexia, a wasting syndrome
observed in patients with advanced HF that has no
accepted definition but is characterized by significant
weight loss in the absence of peripheral edema [30,31].
Studies have demonstrated that many patients with ad-
vanced HF are malnourished, with a calorie and protein
intake that is inadequate to meet their energy require-
ments [32,33]. But, this is unlikely to account for all of
the increased risk as even in the absence of cachexia
studies have shown that the increased risk of HF for the
underweight individual remains [34]. The relationship
between low BMI with increased risk of mortality from
heart failure may also reflect pre-existing heart failure at
study baseline. We did not have information on pre-
valent HF so could not examine this further but in the
sensitivity analysis comparing those with and without a
history of CVD at study baseline, the relationship bet-
ween BMI with mortality from HF was the same.
Perhaps of more relevance to Western countries, is the
increased risk of mortality from HF for obese comparedsmoking (ever versus never) adjusted for age and stratified by
ntions as in Figure 1.
Figure 4 Hazard ratios for fatal heart failure associated with diabetes (yes versus no) adjusted for age and regression dilution bias and
stratified by sex and study in the Asia Pacific Cohort Studies Collaboration. Conventions as in Figure 1.
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authors, have shown. In Framingham, for example, there
was a continuous association between BMI and risk of
new onset HF and each unit increase in BMI was asso-
ciated with a 5% increase in the risk of HF for men and
7% for women [35].
The epidemiological literature describing the relation-
ship between TC and mortality from HF is inconsistent;
some studies have reported a positive [36] or inverse rela-
tion [37] between TC and mortality from HF, but others
including NHANES have shown no association [12]. In
the current study there was no good evidence of an asso-
ciation between TC with mortality from HF –eitherFigure 5 Hazard ratios for fatal heart failure associated with a 1 mmo
dilution bias and stratified by sex and study in the Asia Pacific Cohorpositive or inverse- as shown by the confidence intervals
around the point estimate spanning unity in both the
unadjusted and adjusted models. This is consistent with
randomized data from two clinical trials –CORONA [38]
and GISSI-HF [39]–which demonstrated that in patients
with HF the incidence of cardiovascular events, which are
greatly driven by non-atherosclerotic events, was not im-
portantly affected with statin therapy. Moreover, the Cho-
lesterol Treatment Trialist’s showed that LDL-cholesterol
lowering with statin therapy has no benefit on cardiac
deaths due to non-occlusive mechanisms, such as HF [40].
There are some important limitations of this analysis.
The lack of a universal definition of HF, and betweenl/L increment in total cholesterol adjusted for age and regression
t Studies Collaboration. Conventions as in Figure 1.
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introduced bias. For example, misdiagnosis of HF as
stroke, myocardial infarction or IHD in the early 1990’s
has been suggested to account for the observed increase
in IHD mortality between 1990–1995 in Japan [41]. In the
current analysis, over half of the data from Asia were de-
rived from Japanese cohorts, many of which were initiated
in the early 1990’s. Therefore, it is conceivable that there
was some under-reporting of mortality from HF in these
cohorts; such misclassification is likely to draw estimates
of association towards the null. We also did not have in-
formation on incident heart failure which precludes exa-
mination of the possible effects of reverse causality on the
results (i.e. whether the association between a particular
risk factor with mortality from heart failure is impacted by
the development on heart failure at some point during
follow-up). Another limitation of our data was the lack of
information on rheumatic heart disease, coronary artery
disease and Chagas’ disease, which are major causes of HF
in South Asia and China [8] and which have been reported
to be independent predictors of HF risk [42]. Finally, we
were unable to examine the relationships between emer-
ging cardiovascular risk factors with HF. In a recent report
from the Strong Heart Study, inflammatory markers were
shown to be associated with incident HF, although the re-
lationships were substantially attenuated after adjusting
for more traditional coronary risk factors [43].
Conclusions
In summary, findings from this current study indicate
that several traditional and modifiable cardiovascular
risk factors, namely elevated blood pressure, diabetes,
obesity and cigarette smoking, are independently asso-
ciated with mortality from HF for Asian and non-Asian
populations alike in a broadly consistent manner.
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